Price T Rowe Associates Inc Ascendis Pharma A/S Transaction History

Price T Rowe Associates Inc

$812 Billion
Q1 2025

A detailed history of Price T Rowe Associates Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,256,102 shares of ASND stock, worth $373 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

2,256,102

Previous 2,283,207 1.19%

Holding current value

$373 Million

Previous $314 Million 11.87%

% of portfolio

0.04%

Previous 0.04%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$119.49 - $168.84 $3.24 Million - $4.58 Million	-27,105 Reduced 1.19%	2,256,102 $352 Million
Q4 2024 Feb 14, 2025	BUY	$122.0 - $146.6 $19.8 Million - $23.8 Million	162,079 Added 7.64%	2,283,207 $314 Million
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $38.1 Million - $51.7 Million	336,980 Added 18.89%	2,121,128 $317 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $269,017 - $341,454	2,222 Added 0.12%	1,784,148 $243 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $41.6 Million - $53.7 Million	336,976 Added 23.32%	1,781,926 $269 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $16.6 Million - $24.6 Million	-192,898 Reduced 11.78%	1,444,950 $182 Million
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $36.3 Million - $43.6 Million	-419,316 Reduced 20.38%	1,637,848 $153 Million
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $91.8 Million - $128 Million	-1,312,779 Reduced 38.96%	2,057,164 $184 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $35.7 Million - $43.1 Million	-339,898 Reduced 9.16%	3,369,943 $361 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $16.4 Million - $21.8 Million	-165,022 Reduced 4.26%	3,709,841 $453 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $108 Million - $142 Million	-1,290,512 Reduced 24.98%	3,874,863 $400 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $23.1 Million - $34.7 Million	295,224 Added 6.06%	5,165,375 $480 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $11.1 Million - $14.8 Million	108,958 Added 2.29%	4,870,151 $572 Million
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $9.47 Million - $12.6 Million	-74,521 Reduced 1.54%	4,761,193 $641 Million
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $25.4 Million - $39.9 Million	-225,540 Reduced 4.46%	4,835,714 $771 Million
Q2 2021 Aug 16, 2021	SELL	$121.62 - $145.29 $1.47 Million - $1.76 Million	-12,082 Reduced 0.24%	5,061,254 $666 Million
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $193 Million - $268 Million	-1,545,706 Reduced 23.35%	5,073,336 $654 Million
Q4 2020 Feb 16, 2021	BUY	$151.2 - $182.76 $1 Billion - $1.21 Billion	6,619,042 New	6,619,042 $1.1 Billion

Others Institutions Holding ASND

# of Institutions

272

Shares Held

61.8M

Call Options Held

151K

Put Options Held

226K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $9.24B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Ascendis Pharma A/S Transaction History